ENTA vs. CGEM, ETON, ALT, SANA, MGTX, MAZE, SIGA, ZVRA, SAGE, and AMLX
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
Cullinan Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. Cullinan Therapeutics' return on equity of -26.54% beat Enanta Pharmaceuticals' return on equity.
Enanta Pharmaceuticals currently has a consensus target price of $17.25, suggesting a potential upside of 191.88%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 312.37%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Enanta Pharmaceuticals received 273 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.93% of users gave Cullinan Therapeutics an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote.
Enanta Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 4 mentions for Cullinan Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 0.95 beat Cullinan Therapeutics' score of 0.60 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.
Summary
Enanta Pharmaceuticals beats Cullinan Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ENTA Stock Free ENTA Stock Alerts